Basel, 02 May 2013
Roche Analyst Event at ASCO 2013
Analyst briefing on data presented at ASCO: Sunday, 2 June 2013
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (31 May – 4 June 2013).
Marriott Downtown Chicago
540 North Michigan Avenue
Sunday, 2 June 2013
6:30pm to 8:00pm Central Daylight Time CDT (Chicago)
followed by a buffet reception
- Obinutuzumab (GA101): Final stage 1 results of the CLL11 (BO21004) phase III trial
- Oncology pipeline update
- Oncology business and strategy update
Date:2 June 2013
6:00pm CDTRegistration desk opens
6:30pm CDTStart of meeting
8:00pm CDTEnd of meeting followed by a buffet reception
To register for the event, please follow the link.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.